Bienvenue chez Abnova - distribué au Royaume-Uni et en France par Caltag Medsystems

Featured Apoptosis Research Tools
» Read more
Featured Mitochondria Research Tools
» Read more
English - default ENFrench FR

Abnova: Les anticorps et les protéines recombinantes

Abnova est le plus grand fabricant d'anticorps monoclonal au monde avec une capacité de génération de 300 anticorps monoclonaux de souris et de 200 anticorps polyclonaux de lapin par mois.

Abnova adopte une approche protéomique / génomique pour le développement d'anticorps, leur but étant d'avoir au moins un anticorps pour chaque gène exprimé dans le génome humain. Dans la plupart des cas, plusieurs clones sont disponibles pour les anticorps monoclonaux. Toutes les protéines recombinantes et anticorps sont produits «en interne» dans un établissement à Taiwan.

Abnova offre une production d'anticorps monoclonaux et de protéines qui est différent des entreprises et des laboratoires qui utilisent des méthodes de production traditionnelles. Ils ont une infrastructure à l'échelle industrielle autorisant une production à capacité évolutive : jusqu'à 500 vaccinations par mois, et une installation state-of-the-art exempt d'agents pathogènes, ayant une capacité de plus de 10.000 souris. Ils ont également un système d'expression de la protéine de germe de blé in vitro. Ceci est une installation de production de protéines à haut débit permettant l'expression soluble de la protéine conformationnelle correcte, soit à partir d'ADNc entier ou de domaines spécifiques.

Abnova technologies de production

Caltag Medsystems est un distributeur au Royaume-Uni et en France pour Abnova, apportant un service client et un soutien technique aux scientifiques au Royaume-Uni, en Irlande et en France.

Publications

Protocoles

Ressources

Littérature

Blog posts

nanoCAR-T mRNA Service

Non-viral chimeric antigen receptor (CAR)-T cells are gaining attention for their cancer-killing ability with reduced side effects. Traditional CAR-T…

More

FISH & mutaFISH™ Probes

Abnova has developed a range of FISH probes and validated mutaFISH™ (mutation-specific Fluorescence In Situ Hybridisation) probes.

More

VHH Antibody Applications

VHH Abs, derived from heavy-chain-only IgG Abs in the Camelidae family, present unique & exceptional potential in diverse fields of research/medicine.

More

miRNA In Situ Hybridisation

miRNA in situ hybridisation is a powerful technique that allows researchers to visualise and localise miRNAs within cells and tissues.

More

Documents

  Category Title  
VHH nanoBiTE™ ServiceService DocumentsVHH nanoBiTE™ Service  View
Abnovas VHH nanoBiTE™ service focuses on developing bispecific VHH antibodies without an Fc domain, ideal for immune and tumor cell redirecting, multiple epitope targeting, and novel immuno-oncology research. Their smaller molecular size enhances tissue penetration, making them suitable for hard-to-access areas like the tumor microenvironment. The absence of an Fc region prevents unwanted immune activation by avoiding Fc receptor binding, supporting precise mechanistic action. Engineered through the genetic fusion of two VHH domains via a flexible peptide linker, VHH nanoBiTE™ ensures robust antigen binding with reduced production complexity.  
Neuroscience BioreagentsNeuroscience DocumentsNeuroscience Bioreagents  View
Advanced Solutions to Enhance Neuroscience Research  
CellTx Cell TherapyCell & Gene Therapy DocumentsCellTx Cell Therapy  View
Impactful Bioreagents and Media to Accelerate Cell Therapy Research and Manufacturing  
NanoAb ServiceService DocumentsNanoAb Service  View
Abnova offers the NanoAb™ service for the production of target-specific VHH antibodies from the camelid VHH library.  
Breast Cancer AntibodiesCancer DocumentsBreast Cancer Antibodies  View
Abnova provides a range of antibodies for Breast Cancer.  
Bladder Cancer AntibodiesCancer DocumentsBladder Cancer Antibodies  View
Abnova provides a range of antibodies for bladder cancer.  
New Bioactive ProteinsProteins DocumentsNew Bioactive Proteins  View
Abnovas new bioactive proteins offer exceptional purity and confirmed bioactivity, making them indispensable for various research applications. These proteins, which include CD Proteins, MHC Proteins, Immune Checkpoint Proteins, FGFR Family Proteins, VLP-Displayed Antigens, and other targets, are produced using HEK293 mammalian expression systems to maintain their natural conformation and functionality. All bioactive proteins undergo functional assays to confirm their activity. Through rigorous HPLC analysis, all products achieve over 95% purity. Additionally, the endotoxin levels are less than 1EU/μg detected by the LAL method, ensuring that Abnovas bioactive proteins meet the highest standards for research and therapeutic development.  
Tumour-Associated Antigens of CAR T Cell TherapyCancer DocumentsTumour-Associated Antigens of CAR T Cell Therapy  View
Abnova provides a range of Tumour-Associated Antigens of CAR T Cell Therapy.  
Innate Immunity: TNF-TRAF SignallingImmunology DocumentsInnate Immunity: TNF-TRAF Signalling  View
Abnova provides a range of antibodies for research into TNF-TRAF Signalling.  
The Role of Tumour Necrosis Factor in Amyotrophic Lateral SclerosisNeuroscience DocumentsThe Role of Tumour Necrosis Factor in Amyotrophic Lateral Sclerosis  View
Abnova provides a range of reagents for research into the role of Tumour Necrosis Factor in Amyotrophic Lateral Sclerosis.  
Show more...